Let’s connect at SNMMI2025 in New Orleans! Michael Thiele (CSO) and Friedmund Bachmann (VP CMC) from OncoOne are looking forward to reconnecting with familiar faces and exploring new collaboration opportunities. We’d love to share how our PreTarg-it® platform is shaping the future of pretargeted radioimmunotherapy

Attending BIO-EUROPE Spring? Schedule a one-to-one meeting with OncoOne’s CEO, Randolf Kerschbaumer, CSO, Michael Thiele to learn more about recent and upcoming corporate milestones and to discuss partnering opportunities.  Set up a meeting via the conference’s partnering platform: https://partneringone.informaconnect.com/sign-in  We look forward to seeing you

Join OncoOne at #JPM2025 in San Francisco! From January 13-16, 2025, we’ll be at the J.P. Morgan Healthcare Conference, the premier event for biotech, pharma, and investors.  Meet our CEO Randolf Kerschbaumer and CSO Michael Thiele in person to explore our oxMIF-targeting antibodies for cancer

We’re excited to announce that our CSO, Michael Thiele, will be presenting at the CHIPepTalk Congress on January 14 at 6 PM in the Targeted Radioligand Therapies stream. Don’t miss this opportunity to hear about our innovative Radioimmunotherapy PreTarg-it® platform, which leverages bispecific antibodies for

We’re excited for the Investival Showcase on November 18 in London! Connect with OncoOne’s CEO, Randolf Kerschbaumer, to learn about our oxMIF-targeting antibodies for inflammation and cancer, and the PreTarg-it® platform for targeted radiotherapy. Schedule a meeting via the conference platform: https://informaconnect.com/investival-showcase/ Let’s explore partnering

Mark your calendars for BIOEurope in Stockholm, November 4–6, 2024! Schedule a one-on-one meeting with OncoOne’s CEO, Randolf Kerschbaumer, and CSO, Michael Thiele to learn about our oxMIF-targeting antibodies for inflammation and oncology, and the PreTarg-it® platform for targeted radiotherapy. Explore exciting partnering opportunities with

Are you attending the FestivalOfBiologics in Basel? Don’t miss our CSO, Michael Thiele, presenting “ON104: Pioneering Treatment for oxMIF-Driven Autoimmune Diseases”. It’s a fantastic opportunity to explore the potential of our lead candidate, the anti-oxMIF antibody ON104, as an innovative treatment for autoimmune conditions. Get

Krebsforschungslauf 2024 – This year, we laced up for the first time, running with heart and purpose to support the fight against cancer! On October 5th, the Uni Campus Altes AKH turned into a vibrant running arena for a great cause. With the goal of